

S E C O N D E D I T I O N

Borderline Personality Disorder

A CLINICAL GUIDE

John G. Gunderson, M.D.

WITH
Paul S. Links, M.D., F.R.C.P.C.

BORDERLINE PERSONALITY DISORDER

A Clinical Guide

SECOND EDITION

John G. Gunderson, M.D.

Professor of Psychiatry at Harvard Medical School
Director of Psychosocial and Personality Research and
Director of the Borderline Personality Disorder Center
McLean Hospital
Belmont, Massachusetts

With

Paul S. Links, M.D., F.R.C.P.C.

Professor of Psychiatry at the University of Toronto, Canada



Washington, DC
London, England

Note: The authors have worked to ensure that all information in this book is accurate at the time of publication and consistent with general psychiatric and medical standards, and that information concerning drug dosages, schedules, and routes of administration is accurate at the time of publication and consistent with standards set by the U.S. Food and Drug Administration and the general medical community. As medical research and practice continue to advance, however, therapeutic standards may change. Moreover, specific situations may require a specific therapeutic response not included in this book. For these reasons and because human and mechanical errors sometimes occur, we recommend that readers follow the advice of physicians directly involved in their care or the care of a member of their family.

Books published by American Psychiatric Publishing, Inc., represent the views and opinions of the individual authors and do not necessarily represent the policies and opinions of APPI or the American Psychiatric Association.

The authors of this book, John G. Gunderson, M.D., and Paul S. Links, M.D., F.R.C.P.C., have no competing interests to disclose.

Copyright © 2008 American Psychiatric Publishing, Inc.
ALL RIGHTS RESERVED

Manufactured in the United States of America on acid-free paper

12 11 10 09 08 5 4 3 2 1

Second Edition

Typeset in Adobe's New Baskerville and AvantGarde

American Psychiatric Publishing, Inc.

1000 Wilson Boulevard

Arlington, VA 22209-3901

www.appi.org

Library of Congress Cataloging-in-Publication Data

Gunderson, John G., 1942–

Borderline personality disorder : a clinical guide / John G. Gunderson with Paul S. Links. — 2nd ed.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-58562-335-8 (alk. paper)

1. Borderline personality disorder. I. Links, Paul S. II. Title.

[DNLM: 1. Borderline Personality Disorder. WM 190 G975ba 2008]

RC569.5.B67G863 2008

616.85'852—dc22

2008005061

British Library Cataloguing in Publication Data

A CIP record is available from the British Library.

CONTENTS

About the Authors	xi
Introduction	xiii
1 The Borderline Diagnosis	1
Origins of the Diagnosis	1
Shifts in the Borderline Construct: From Organization to Syndrome to Disorder	5
Epidemiology	9
An Explication of the DSM-IV Criteria	9
A Clinical Synthesis: Intolerance of Aloneness	18
Misuses of the Borderline Diagnosis	22
The Behavioral Specialty: Self-Injurious Behavior	24
Use of the Diagnosis in Adolescents	27
How to Explain the Diagnosis	27
Summary	28
References	28
2 Differential Diagnosis: Overlaps, Subtleties, and Treatment Implications	37
Overall Function	37
The Changing Construct: From Schizophrenia to Depression to Posttraumatic Stress Disorder to Bipolar Disorder	38
Comorbidity and Differential Diagnosis	40
Summary	59
References	60

3	Overview of Treatment	65
	Historical Overview	65
	Generic Therapeutic Processes and the Functions They Serve	67
	Multiple Modalities and Step-Down Services: An Overview	71
	Sociotherapies	72
	Establishing Goals: The Expectable Sequence of Change	72
	Changes Within Four Spheres	77
	The Initial Structuring of Treatment	80
	Types and Sequence of Therapeutic Alliance	82
	Countertransference	84
	Summary	85
	References	85
4	Case Management: The Primary Clinician	89
	Qualifications	90
	Responsibilities	90
	Liability Issues	92
	Relationship Management	93
	Managing Safety	94
	Responding to Recurrent Suicidality: The Principle of False Submission	102
	Implementing Changes	105
	Boundaries, Violations, and Setting Limits	106
	Splits, Splitting, and the Virtues of Split Treatments	107
	Giving, Receiving, and Participating in Supervision	110
	Summary	110
	References	111
5	Levels of Care: Indications, Structure, Staffing	113
	Selecting or Changing a Level of Care	114
	Level IV: Hospital Treatment—Makes Therapy Possible ...	115
	Level III: Residential/Partial Hospital Care/ Day Treatment—Basic Socialization	122
	Level II: Intensive Outpatient Care— Behavioral Change	130
	Level I: Outpatient Care—Interpersonal Growth	133
	Summary	134
	References	135

6 Pharmacotherapy: Clinical Practices 139

History	139
Overall Role of Medications	140
Getting Started	143
The Prescribing Psychiatrist's Role	143
Symptom Chasing	148
Attitudes, Meanings, and Attributions	148
Transference-Countertransference Issues	149
Contraindications and Discontinuance	151
Summary	153
References	153

7 Pharmacotherapy: Selection of Medications 157

Pharmacotherapy Models	157
The Symptom-Targeted Model	158
Summary	169
References	170

8 Family Interventions and Therapies 177

History	178
Therapists and Countertransferences	180
Getting Started: Overcoming Resistance	181
Phase 1: Initial Family Meetings	183
Phase 2: Establishing an Alliance	187
Phase 3: Psychoeducational Family Therapy	189
Phase 4: Psychodynamic Family Therapy	196
Marital or Couples Therapy	197
Summary	201
References	201

9 Group Therapy 207

Indications	207
Engaging Patients and the Primary Clinician's Role	208
Skills Training Groups	209
Psychodynamic Group Therapies	214
Group Structure	216
Common Problems	218
Summary	222
References	222

10	Individual Psychotherapies: Getting Started	225
	Introduction: Prerequisites	225
	Getting Started	227
	Structuring the Therapeutic Frame (External Boundaries)	231
	Therapists	236
	Engagement	243
	Generic Qualities of Effective Psychotherapies	247
	Summary	250
	References	250
11	Cognitive-Behavioral Therapies: Dialectical Behavior Therapy and Cognitive Therapies	253
	Overview	253
	Basic Operant Conditioning Applications for All Treatment Settings	255
	Dialectical Behavior Therapy	256
	Cognitive Therapies	267
	Summary	274
	References	274
12	Psychodynamic Psychotherapies	279
	Pre-Empirical Developments	280
	Outcome Studies: Nonrandomized Trials	282
	Transference-Focused Psychotherapy	286
	Overview of Change Processes	289
	Phase 2: A Relational Alliance	291
	Phase 3: Positive Dependency	298
	Phase 4: Secure Attachment, the Working Alliance, and Consolidation of Self	304
	Impasses	305
	Summary	307
	References	307
13	Future Considerations	315
	Treatment Implications	315
	Diagnostic Implications	318
	Public Awareness and Advocacy	321
	Summary	324
	References	325

Appendix Psychoeducational Resources:
Printed Materials, Videos, Films, and Web Sites . . . 329

Printed Materials 329
 Videos 331
 Films 331
 Web Sites 332

Index 337

List of Sidebars

1-1: Where Were the Borderline Patients Before the Diagnosis? 2
 1-2: The Subjective Experience of Being Borderline 13
 1-3: Borderline Personality as an Iatrogenic Disorder 15
 1-4: British Developmentalists: From Winnicott to Bowlby to Fonagy 18
 1-5: "Wisdom Is Never Calling a Patient Borderline" 23
 1-6: Cutting: Social Contagion or Psychopathology? 26
 2-1: Was Vincent van Gogh Borderline? 46
 2-2: Is Martha Stewart Borderline? 53
 3-1: Should Consumers Receive Progress Reports? 74
 3-2: Myths About Alliance With Borderline Patients 83
 4-1: Guidelines to Avoid Liability 93
 4-2: Is Contracting for Safety Safe? 99
 5-1: Can Long-Term Hospitalization Be Desirable for BPD? 115
 5-2: How Psychotherapeutic Technique Relates to Level of Care 121
 5-3: Vocational Counseling: Should a Borderline Patient Return to School, Pursue a Career, or Become a Caregiver? 123
 5-4: Empirical Support for a Specialized "Mentalization-Based" Day Hospital 128

6-1: Listening to Prozac: Can Selective Serotonin Reuptake Inhibitors Cure BPD?	141
6-2: Liability Hazards of Split Treatment	147
8-1: "You Can't Talk to My Parents"	182
8-2: Families of Married Borderline Patients	184
8-3: Finessing the Guilt Issue	186
8-4: "Good Cop/Bad Cop": A Parental Problem	191
8-5: Makes Sense, But Does it Work? Preliminary Findings of the Psychoeducational Multiple-Family Group	195
9-1: Research on Interpersonal Group Therapy With BPD	215
10-1: Quality Assurance: Should Therapists Be Credentialed to Treat BPD?	240
10-2: Listening to Kernberg or Linehan: Can Charisma Cure BPD?	242
11-1: Schema-Focused Therapy: Does It Work?	269
12-1: Kernberg Versus Kohut/Adler: The Debate of the 1970s	280
12-2: Kernberg Versus Linehan: The Debate of the 1990s	286
12-3: Transitional Objects: From Concept to Phenomenon	298
12-4: Is Regression Therapeutic? The Two Margarets	302
13-1: Were a Famous Borderline Person to Go Public...	323

ABOUT THE AUTHORS

John G. Gunderson, M.D., is Professor of Psychiatry at Harvard Medical School, Boston, Massachusetts. At McLean Hospital in Belmont, Massachusetts, he serves as Director of Psychosocial and Personality Research and of the Borderline Personality Disorder Center.

Dr. Gunderson has been integrally involved in the diagnosis and treatment of borderline personality disorder since 1969. His studies helped to define the diagnosis of borderline personality disorder and establish an empirical standard for evaluating treatment of this disorder.

Paul S. Links, M.D., F.R.C.P.C., is Professor of Psychiatry at the University of Toronto, Canada. At St. Michael's Hospital, he is serving his third term as the Arthur Sommer Rotenberg Chair in Suicide Studies.

INTRODUCTION

THIS BOOK IS A SEQUEL to *Borderline Personality Disorder: A Clinical Guide*, published in 2001, which was a sequel to *Borderline Personality Disorder*, published in 1984. These books have summarized what was known—or believed—about treating borderline personality disorder (BPD) at the time of their publication. This revision of the 2001 book updates the rapidly expanding treatment literature. Clinical perspectives, concepts, and modalities continue to become more sophisticated, detailed, and empirically buttressed. A great deal is currently known about what to do and, just as important, what not to do to treat BPD effectively. After only a 7-year interval, a significant revision was needed to accommodate the mushrooming of information, expertise, and specialization.

This book is meant to cover comprehensively all the recognized therapies for BPD. It details long-term multimodal treatment, with an appreciation that no one modality is by itself sufficient. I attempt to emphasize advances from empirical research and to synthesize them with what is feasible and with what derives from clinical experience. Above all, this book is meant to be useful and practical, primarily for clinicians, but also potentially for trainees, patients' families, and health care administrators. Although no treatment is excluded from consideration because of its cost, all treatments are considered with issues of cost-effectiveness and feasibility in mind.

The first chapter covers the issue of the diagnosis itself: what the diagnosis means and the biases that affect its use. Special attention is given to the borderline patients' behavioral specialty (i.e., their self-destructiveness) and to the use of this diagnosis in adolescents. Perhaps the most important message for clinicians is that we do these patients (and their families) a favor by identifying the diagnosis and educating them about it. Patients and families deserve to know what is known, and, as often as not, the success of treatments rests on their being included as responsible allies.

Chapter 2 describes BPD's most common differential diagnostic issues. These have shifted from schizophrenia to depression to posttraumatic stress disorder to the current controversy about the interface with bipolar disorder. The last issue is now given more attention.

Three theories guide most clinicians—biological, cognitive-behavioral, and psychodynamic. My psychodynamic background inevitably anchors much of this book, but the theory most central to this book's goals is a theory about therapies found in Chapter 3. Chapter 3 offers an empirically and clinically anchored theory on the sequencing of goals (i.e., targets for intervention), on processes of change, and on the modalities that are best suited for a patient's changing needs. The chapter underscores the feasibility and value of establishing initial short-term goals. In this chapter, I also describe the basic role of psychoeducation for patients and families—both as a way to establish an alliance with longer-term goals and as a therapeutic intervention in its own right. Psychoeducation superimposes a logic on treatment planning, and it anticipates the sequence of the chapters that compose the rest of the book.

After Chapter 3, the book proceeds to chapters concerning the implementation of overall treatment plans (Chapters 4 and 5). These chapters emphasize the need for someone to develop the plan, establish an appropriate level of care, and include rehabilitative services that address the borderline patients' typically severe impairments in social functioning. Chapters 6 through 12 describe the specific modalities in a sequence consistent with the severity of the borderline patient's mental state and with the length of time needed to meet the primary goals of each modality.

Chapter 4 outlines the primary clinician's responsibilities. In an era when managed care hovers in the background of treatment authorization, and in which care of borderline patients moves across multiple settings, it is easy to ignore the central requirement of having some one clinician be identified to all, including the patient, as being in charge—the *primary* clinician. This chapter introduces the thesis that rather than being problematic, *split treatments* that emerge from the current multimodal, multitreater environment are treatment enhancing. This book repeatedly points out how a treatment having two or more components not only adds breadth to the treatment goals but also offers a structure that safeguards treatment against the borderline patients' enactment of their intrapsychic splits.

Chapter 5 concerns four levels of care. Here empirical evidence is introduced about the potential value of the two most intensive levels: hospital care (level IV) and residential or partial hospital (level III). The four levels are not seen here as competitive but as having different goals, durations (this was intended 7 years ago), structures, and staffing. Of most interest may be the endorsement given to a newer level of care, intensive outpatient programs. Intensive outpatient programs represent a level of care that, although not widely available, may be more effective and certainly more cost-beneficial than relying on hospital or partial hospital services.

Reflecting the fact that medications have quietly become the single most widely and uniformly used treatment for BPD, two chapters (6 and 7) are devoted to psychopharmacology. Chapter 6 offers an extensive account of the seemingly irrational *in vivo* complexities surrounding prescribing medications and evaluating their effectiveness. In contrast, Chapter 7 offers a rational algorithm to guide selection of medications that should usefully inform prescribing physicians.

Chapter 8 encourages clinicians to involve families far more than has been customary. I describe how clinicians can use consumer-friendly psychoeducational interventions. Note that many interventions, albeit brief and not called therapies, may be very valuable. Furthermore, use of traditional dynamic family therapies is reserved for only selected cases and then only in a late stage of treatment. For most families, the primary treatments are parental coaching and assisted problem solving. Preliminary data that show the value of such coaching and problem solving are offered.

Chapter 9 underscores the role that interpersonal groups should play in the first year or so of most borderline patients' treatment. This type of treatment is readily exportable and nicely complements the functions served by individual therapies or psychopharmacology by addressing the interpersonal impairment that is central to most borderline patients' disorder. The available empirical evidence underscores the need for more use of and more research on interpersonal groups.

In Chapter 10, I argue that initiating individual psychotherapy should be done selectively, taking into account the motivation, the aptitude, and the social supports required of both patients and therapists. Otherwise skilled cognitive-behavioral or dynamically oriented therapists still need special training and experience, and perhaps special personality traits, to do such therapies well. Chapter 10 also outlines some of the general overlapping characteristics of all effective psychotherapies.

Although cognitive-behavioral principles have always been needed for adequate treatment of BPD, Chapter 11 recognizes that specific types of cognitive-behavioral treatments have now become the cornerstone for much modern theory and practice. Indeed, dialectical behavior therapy (DBT) has rapidly become the most BPD-specific and empirically substantiated treatment for BPD. Unquestionably, DBT was the major advance in therapeutics of the 1990s. Chapter 11 tries both to acquaint the uninitiated with DBT and to place it in some perspective. Other notable developments cited in Chapter 11 include the recent addition of a promising second empirically validated cognitive-behavioral treatment, schema-focused psychotherapy, and evidence for the potential for short-term cognitive-behavioral therapies to be effective for discrete goals.

Chapter 12 is devoted to psychodynamic (i.e., psychoanalytic) psychotherapy, the modality that for several decades was considered the treatment of choice for BPD. Chapter 12 highlights the long-needed emergence of empirical support for Kernberg's transference-focused form of therapy. It also delineates the phases of psychotherapeutic progress and change over a period of 4 or more years. Both the corrective power of the relationship and the growth made possible by learning (i.e., insights) are described. The case is made that progress should be ongoing, and its absence should be cause for review and consultation. This optimistic message is set against the need for a protracted multiyear process.

Chapter 13 begins by noting that the borderline diagnosis has achieved a place in the consciousness of the mental health world, but it is only beginning to establish a place in the public consciousness. The development and influence of the Borderline Personality Disorder Research Foundation, the explicit recognition of a need for more research on BPD by the National Institute of Mental Health, the rise of family advocacy groups, and the adoption of BPD as a brain disease by the National Alliance on Mental Illness dramatically signal that this expansion is under way. Chapter 13 also introduces how the rise in neurobiological research is likely to greatly transform our understanding of borderline patients.

The remarkable advancements in treatment for BPD described and celebrated in this book can be expected to continue. The current diversity of theory and research creates a healthy, vibrant vehicle for continued growth.

Borderline patients require an array of clinical services, any of which can be harmful or helpful. But to treat this disorder effectively requires clinicians with specialized knowledge and training. When such conditions are present, beneficial changes occur that greatly reduce patients' dysphoric mental states and enhance social functioning. Effective treatment results in a concurrent reduction in the burden on borderline patients' significant others, an improved morale by treaters, and a decrease in the otherwise enormous public health costs.

Chapter 1

THE BORDERLINE DIAGNOSIS

THE BORDERLINE PERSONALITY DISORDER (BPD) diagnosis entered the American Psychiatric Association's DSM-III in 1980 (American Psychiatric Association 1980) and 12 years later, in 1992, was adapted for the World Health Organization's ICD-10 (World Health Organization 1992). The growth in the recognition and use of this diagnosis during the period from 1975 to 1990 has been remarkable. It is easily the most widely and commonly used diagnosis for personality disorders in modern clinical practice (Loranger 1990; Loranger et al. 1997). Individuals with BPD constitute about 2%–3% of the general population (Swartz et al. 1990; Zimmerman and Coryell 1989), about 25% of all inpatients, and about 15% of all outpatients (Koenigsberg et al. 1985; Widiger and Weissman 1991).

Origins of the Diagnosis

The origins of the borderline diagnosis, illustrated in Figure 1–1, are usually traced to the clinical observations of Adolph Stern (1938), a psychoanalyst in office practice, who recognized that a subgroup of his patients disregarded the usual boundaries of psychotherapy and did not fit into the existing classification system, a system concerned primarily with dividing psychoses from neuroses. A scholarly review of the work preceding Stern's can be found in Mack (1975). The patient group became somewhat more widely recognized in the early 1950s as a result of several influential papers by Robert Knight (1953, 1954). He expanded the descriptor *borderline* from relating to only the border with neurosis to being equally relevant to the border with psychosis. Like Stern, he began by decrying the “wastebasket” diagnostic status for such patients. However, he added that failure to identify the unique needs of these patients was responsible for the troubling disagreements between staff members on inpatient units; he further stated that this failure led clinicians to ignore providing the structure such




FIGURE 1-1. Development of the borderline construct, I.

BPD=borderline personality disorder; BPO=borderline personality organization; BSz=borderline schizophrenia; STPD=schizotypal personality disorder.

patients needed to avoid regressing. After Knight, the term *borderline* to denote troublesome patients who were neither psychotic nor neurotic retained some currency but primarily within the community of psychoanalysts who worked in hospital settings (Sidebar 1-1).

Sidebar 1-1: Where Were the Borderline Patients Before the Diagnosis?

A review of medical records from Danish and British psychiatric institutions before the diagnosis was used showed that borderline patients existed (Gunderson et al. 1983; Kroll et al. 1982). Although Freud himself used the term *borderline* only to differentiate delinquent acting-out adolescents from those with neuroses (Aichhorn 1925/1945, Introduction), years later Wolberg (1973) rediagnosed one of Freud's most famous patients, the "Wolf Man," as being borderline. Certainly, before the diagnosis, clinicians (Aichhorn 1925/1945; Alexander 1930; W. Reich 1949) described impulse-driven disorders presaging what was to become the BPD diagnosis. Therefore, there is every reason to believe that borderline patients were present in clinical settings long before the diagnosis.

Still, it is possible that what was formerly rare is now far more common. Grinker et al. (1968) suggested that bor-

derline psychopathology is a by-product of social changes during the twentieth century. The earlier burdens of manual labor and the earlier restrictions of travel, communication, and leisure time may have offered the structure, survival activities, and monitors that silently kept such psychopathology in check. Millon (1987) developed a thesis (subsequently elaborated by Paris (1992)) about sociocultural causes for BPD that, if taken to its extreme, is consistent with the possibility that BPD would have been far less common in other eras. At present, this thesis can be tested only by epidemiological work showing whether the incidence and prevalence of BPD vary between cultures and their levels of modernity.

Use of the term *borderline* for atypical, clinically troubling cases staggered along in the periphery of psychiatric thinking without notable progress until developments in the late 1960s. At this point, the confluence of three independent investigations forced the questions about a borderline consciousness.

The first of these investigations came from Otto Kernberg (1967). Even as a relatively young man, Kernberg authoritatively added to the psychoanalytic perspective of the borderline construct. He defined *borderline personality organization* as one of three forms of personality organization, to be differentiated from sicker patients, who had *psychotic personality organization*, and healthier patients, who had *neurotic personality organization* (Figure 1–2). Borderline personality organization was characterized by failed or weak identity formation, primitive defenses (namely, splitting and projective identification), and reality testing that transiently lapsed under stress. Kernberg's scheme was a conceptual advance within the psychoanalytic community by virtue of integrating object relations with ego psychology and the instincts and by virtue of giving a rationale and organization to a basic classification system. However, the effect of his scheme within the larger mental health community derived more from the optimistic therapeutic mandates that he gained from his way of understanding these patients than from the concept itself (see Kernberg 1968, 1975).

The second seminal contribution was provided by Roy Grinker et al. (1968), a senior and respected statesman within American psychiatry. Armored with a brief personal analysis by Freud himself, Grinker had become chairman of psychiatry at The University of Chicago and editor of the *Archives of General Psychiatry*. As one of the early champions of the need for empirical research, and having already made major contributions to studies of depression and posttraumatic stress disorder (PTSD), Grinker undertook the first empirical study of borderline patients. With